- Location
Novo Nordisk
"-
Novo Nordisk Announced The Launch of The Insulin Delivery Device NovoPen Echo
Jan 21, 2014Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo® in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory ...
-
Trialbee Has Developed a Web Based Platform and Methodology
Jan 20, 2014Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in ...
-
Tretten Has Been Approved by FDA to Treat a Very Rare Blood Clotting Disorder
Dec 25, 2013Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency. People with the genetic ...
Tags: Tretten, blood clotting disorder
-
2014 Will Be a Turnaround Year in That Regard
Dec 17, 2013Hopefully as you are reading this, you are enjoying the holiday season and getting ready for 2014. It's been a chaotic, uneven 2013, and my wish is to see it over with as soon as possible and make a fresh start. Not all of 2013 has been ...
-
Insulin Pump Therapy for Diabetics Get Easier Due to Novo Nordisk and Roche Diabetes
Nov 26, 2013Denmark-based Novo Nordisk has announced that the European Medicines Agency (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing of the NovoRapid PumpCart in Europe. NovoRapid PumpCart is a 1.6ml ...
-
FDA Approval Were Obtained by Novo Nordisk for Two Prefilled Insulin Pens
Nov 5, 2013Denmark-based medical device company Novo Nordisk has obtained the US Food and Drug Administration (FDA) approval for its NovoLog (insulin aspart [rDNA origin] injection) FlexTouch and Levemir (insulin detemir [rDNA origin] injection) ...
-
Novo Nordisk Has Obtained an Approval From Health Canada for The Levemir FlexTouch
Oct 22, 2013Global healthcare company Novo Nordisk has obtained an approval from Health Canada for the Levemir FlexTouch, a new disposable insulin injection pen device for use in insulin-treated patients with type 1 and type 2 diabetes mellitus. Novo ...
Tags: Novo Nordisk, Insulin Pen
-
Novo Nordisk Has Received Approval From Health Canada for Its Levemir Flextouch
Oct 22, 2013Novo Nordisk has received approval from Health Canada for its Levemir FlexTouch, a disposable prefilled insulin pen containing Levemir (insulin detemir), designed to treat patients with type 1 and type 2 diabetes. FlexTouch has an easy ...
Tags: Treatment of Diabetes, Insulin Pen
-
Novo Nordisk Has Received Biologics Licence Application Approval From FDA
Oct 18, 2013Danish pharmaceutical firm Novo Nordisk has received biologics licence application (BLA) approval from the US Food and Drug Administration (FDA) for its recombinant coagulation factor VIII, Novoeight. Novoeight is intended for adults and ...
Tags: Novo Nordisk, Drug
-
EMA Gives Positive Opinion to Novo Nordisk for Novoeight
Sep 24, 2013Danish pharmaceutical company Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing approval for its NovoEight (turoctocog alfa), ...
Tags: Novo Nordisk, Novoeight
-
Novo Nordisk Has Won US FDA 510(K) Clearance for NovoPen Echo
Aug 26, 2013Denmark-based health care company Novo Nordisk has won US FDA 510(k) clearance for the insulin injection device, NovoPen Echo, combining half-unit dosing with a memory function to help patients manage their diabetes. Available to patients ...
Tags: Insulin Injection, Medicine
-
Adimab Signed a Multi-Target Discovery Agreement with Celgene Corporation
Aug 22, 2013Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms ...
Tags: Adimab, Drug Discovery
-
Novo Nordisk Has Announced Plans to Launch Its Obesity Treatment Drug
May 27, 2013Global healthcare company Novo Nordisk has announced plans to launch its obesity treatment drug, liraglutide, in the US by the end of 2014. Novo chief scientific officer Mads Thomsen was quoted by health24.com as saying that liraglutide ...
Tags: Obesity Drug, Medicine
-
Peder Holk Nielsen Takes Office as President & CEO of Novozymes
Apr 2, 2013Peder Holk Nielsen takes office as President & CEO of Novozymes. "I am proud and honored to lead this great company forward," says Peder Holk Nielsen. "Novozymes is in a very strong position, and we will continue with our overall ...
Tags: Industrial Equipment, Textile
-
FDA Has Granted Regulatory Approval to Novo Nordisk Dorinsulin Delivery Device in China
Mar 12, 2013Tianjin Food and Drug Administration has granted regulatory approval to Novo Nordisk to market its new insulin delivery device in China. The NovoPen 5 device, which has the same benefits as its predecessor NovoPen 4 in terms of the design ...
Tags: Novo Nordisk, Chinese Approval, Insulin Delivery Device
